ChilliPharm Data-driven insights: How digital media can help clinical trials succeed

Allison Morgan (1).png

In this blog, Allison Morgan, Clinical Development Consultant at Chillipharm summaries the  newly published White Paper from ChilliPharm which highlights how the power of digital media can be harnessed to provide real world evidence by combining traditional clinical data sources with untraditional ones such as videos, audio files, and photographs which can transform the evaluation of new therapeutics, offering a deeper understanding of diseases and capturing the patient experience like never before.

The filming or photographing of endpoint assessments and milestones at key stages throughout a trial can provide invaluable visual evidence of the efectiveness of the compound being trialled. However, compliance and privacy are paramount in this digital landscape, where personal information must be safeguarded, and strict regulations and protocols must be adhered to. ChilliPharm’s specialist video platform and anonymisation and redaction services ensure that this vital visual evidence can be securely and compliantly shared with stakeholders and regulatory authorities, helping to accelerate regulatory approvals.

ChilliPharm’s publication examines the ethical considerations, the challenges of data protection, and the need for strict compliance. Discover how using clinical digital assets are revolutionizing the way we conduct research, elevating the patient voice with visual evidence, and shaping the future of both drug and device evaluation and approval.

The paper outlines the rapidly growing field of real world evidence that is paving the way for enhanced healthcare outcomes and will help you embrace the digital revolution and embark on a journey where data meets compassion, innovation meets compliance, and patients are at the heart of it all.

About Chillipharm 

ChilliPharm provides unique end-to-end compliant services that enable the capture, management and de-identification of video evidence in clinical outcome assessments to increase regulatory submission success.


More news and updates 

CEO Update - 10 June 2024

UK General Election and what it might mean for the industry, including Labour's pledges on Brexit and business taxes. Upcoming events including the Cambridge Wide Open Day and the Life Science Leadership Summit. UK tech companies pitching at the London Stock Exchange and Amber Therapeutics securing $100 million in funding.

Women in Biotech Mentoring Programme: Dr Carolina Grandellis

In this interview, Dr Carolina Grandellis, Lead of the Earlham Institute Biofoundry, explores the profound impact of the BIA's Women in Biotech mentoring programme on her professional and personal life.

An urgent call for technical standards and metrics for engineering biology

There are currently very few technical standards and metrics that are specific and appropriate to the field of engineering biology. Across the innovation pipeline, there are opportunities for standards to support faster development and enable accelerated commercialisation of the bioeconomy. In response to this, an effort was undertaken with the objective of identifying key areas where standards and metrics would enable the growth of the global bioeconomy.

CEO Update - 3 June 2024

MSD Merck acquire UK biotech EyeBio for $1.3 billion upfront, ASCO and BIO conference week and the UK General election campaign produces little news for the life science sector.

CEO Update - 28 May 2024

The UK General Election has been called for Thursday, 4 July. In practical terms, this means the end of the legislative pathway for many proposals as Parliament shuts down. Keep reading for updates on our general election webinars and UK events at BIO 2024.

CEO Update - 20 May 2024

The UK continues to lead the global discussion on tackling the antibiotic emergency. Last week saw leading global figures convene at the Royal Society to pledge money and agree actions on the AMR agenda.

Spotlight on hearing therapeutics landscape: a clinical perspective

Professor Gerard O’Donoghue shares his perspective as Consultant Neurotologist at Nottingham University Hospitals NHS Trust on why he believes that the development of new treatments and their subsequent clinical adoption are vital for people living with hearing loss.

Deep Biotech companies using engineering biology for good: Epoch Biodesign case study

Featured in BIA's Deep Biotech report, Epoch Biodesign aims to revolutionize plastic waste management by creating tailor-made enzymes that efficiently depolymerize a wide range of plastics into recyclable materials, offering a circular solution to tackle plastic pollution and promote sustainability.

Women in Biotech Mentoring Programme: Helen and Kathryn's experience

In this interview, consultant and best-selling author Kathryn Simpson, together with patent attorney Helen Bartlett, dive into their reasons for joining the BIA's Women in Biotech mentoring programme, and how this experience has impacted their professional and personal lives.

Deep Biotech companies using engineering biology for good: Solena Materials case study

Solena Materials is a pioneering biotech company spun out from Imperial College London, specialising in the development of computationally designed synthetic protein materials, originally featured in BIA's Deep Biotech report on disruptive innovation for global sustainability.


More within